LaMond Stephen J's Form 4/A amendment
AmendedPeak Bio, Inc. (PKBO) · filed Sep 28, 2023
- Accession no.
- 0000950170-23-050434
- Filed
- Sep 28, 2023
- Trade date
- Sep 15-18, 2023
- Filing delay
- 13 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Sep 19, 2023
This filing lists 2 non-derivative transactions. It was filed 13 days after the trade.
This amendment replaces 0000950170-23-048775 (filed Sep 19, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LaMond Stephen JCIK 0001951073 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Dr. LaMond previously reported purchases of 26,000 shares of the Company's Common Stock on September 15, 2023 in error. Instead, on September 15, 2023, Dr. Stephen LaMond purchased a total of 11,750 shares of the Company's Common Stock at prices ranging from $0.27 per share to $0.43 per share.
Referenced by the price of 1 transaction in Table I.
- F2
On September 18, 2023, Dr. Stephen LaMond purchased a total of 2,500 shares of the Company's Common Stock at prices ranging from $0.23 per share to $0.29 per share.
Referenced by the price of 1 transaction in Table I.
Remarks
Interim Chief Executive Officer